- Home
- FRA vs REVBW Comparison
FRA vs REVBW Comparison
Compare FRA & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRA
- REVBW
- Stock Information
- Founded
- FRA 2003
- REVBW N/A
- Country
- FRA United States
- REVBW United States
- Employees
- FRA N/A
- REVBW 9
- Industry
- FRA Investment Bankers/Brokers/Service
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- FRA Finance
- REVBW Health Care
- Exchange
- FRA Nasdaq
- REVBW Nasdaq
- Market Cap
- FRA N/A
- REVBW N/A
- IPO Year
- FRA N/A
- REVBW 2020
- Fundamental
- Price
- FRA $13.89
- REVBW $0.01
- Analyst Decision
- FRA
- REVBW
- Analyst Count
- FRA 0
- REVBW 0
- Target Price
- FRA N/A
- REVBW N/A
- AVG Volume (30 Days)
- FRA 165.4K
- REVBW N/A
- Earning Date
- FRA 01-01-0001
- REVBW N/A
- Dividend Yield
- FRA 11.06%
- REVBW N/A
- EPS Growth
- FRA N/A
- REVBW N/A
- EPS
- FRA N/A
- REVBW N/A
- Revenue
- FRA N/A
- REVBW N/A
- Revenue This Year
- FRA N/A
- REVBW N/A
- Revenue Next Year
- FRA N/A
- REVBW N/A
- P/E Ratio
- FRA N/A
- REVBW N/A
- Revenue Growth
- FRA N/A
- REVBW N/A
- 52 Week Low
- FRA $11.33
- REVBW N/A
- 52 Week High
- FRA $13.10
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- FRA 51.43
- REVBW N/A
- Support Level
- FRA $13.82
- REVBW N/A
- Resistance Level
- FRA $14.09
- REVBW N/A
- Average True Range (ATR)
- FRA 0.15
- REVBW 0.00
- MACD
- FRA -0.03
- REVBW 0.00
- Stochastic Oscillator
- FRA 17.50
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).